- The stock price of Senti Biosciences (SNTI) surged by over 20% pre-market today. This is why.
The stock price of Senti Biosciences (SNTI) surged by over 20% pre-market today.
Why: Bullish research report
Price target: $7
Analyst: BofA Securities analyst Greg Harrison
Harrison adjusted the rating while noting that Senti’s gene circuit platform is differentiated and offers the potential to attack new cancer targets with fewer on-target off-tumor effects compared to current approaches. And Harrison sees a significant unmet need in the initially targeted indications of acute myeloid leukemia and hepatocellular carcinoma and thinks peak unadjusted revenues greater than $1 billion in 2031.